{"id":"https://openalex.org/W2467225938","doi":"https://doi.org/10.1182/blood.v112.11.1945.1945","title":"A Phase 1 Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias.","display_name":"A Phase 1 Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias.","publication_year":2008,"publication_date":"2008-11-16","ids":{"openalex":"https://openalex.org/W2467225938","doi":"https://doi.org/10.1182/blood.v112.11.1945.1945","mag":"2467225938"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v112.11.1945.1945","doi":"https://doi.org/10.1182/blood.v112.11.1945.1945","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v112.11.1945.1945","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5041443589","display_name":"Jeffrey E. Lancet","orcid":"https://orcid.org/0000-0002-7751-7310","observed_orcids":["https://orcid.org/0000-0002-7751-7310"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey E. Lancet","raw_affiliation_strings":["H. Lee Moffitt Cancer Ctr. & Rsrch. Institute, Tampa, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Ctr. & Rsrch. Institute, Tampa, FL, USA","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111876734","display_name":"Elliott F. Winton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]},{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elliott F. Winton","raw_affiliation_strings":["Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA","institution_ids":["https://openalex.org/I150468666","https://openalex.org/I4390039307"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015493242","display_name":"Robert Kenneth Stuart","orcid":"https://orcid.org/0000-0001-7549-8008","observed_orcids":["https://orcid.org/0000-0001-7549-8008"]},"institutions":[{"id":"https://openalex.org/I153297377","display_name":"Medical University of South Carolina","ror":"https://ror.org/012jban78","country_code":"US","type":"education","lineage":["https://openalex.org/I153297377"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert K. Stuart","raw_affiliation_strings":["Medical Univ. of S. Carolina, Charleston, SC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Univ. of S. Carolina, Charleston, SC, USA","institution_ids":["https://openalex.org/I153297377"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103517693","display_name":"Michelle K. Burton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michelle Burton","raw_affiliation_strings":["H. Lee Moffitt Cancer Ctr. & Rsrch. Institute, Tampa, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Ctr. & Rsrch. Institute, Tampa, FL, USA","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036862186","display_name":"Christopher L. Cubitt","orcid":"https://orcid.org/0000-0001-6343-7451","observed_orcids":["https://orcid.org/0000-0001-6343-7451"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher Cubitt","raw_affiliation_strings":["H. Lee Moffitt Cancer Ctr. & Rsrch. Institute, Tampa, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Ctr. & Rsrch. Institute, Tampa, FL, USA","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103527984","display_name":"Michelle A. Blaskovich","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michelle Blaskovich","raw_affiliation_strings":["H. Lee Moffitt Cancer Ctr. & Rsrch. Institute, Tampa, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Ctr. & Rsrch. Institute, Tampa, FL, USA","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":null,"display_name":"John Wright","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Wright","raw_affiliation_strings":["IDB CTEP NCI, Rockville, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"IDB CTEP NCI, Rockville, MD, USA","institution_ids":["https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103060677","display_name":"Sa\u0131\u0308d M. Sebti","orcid":"https://orcid.org/0000-0001-5163-1038","observed_orcids":["https://orcid.org/0000-0001-5163-1038"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Said Sebti","raw_affiliation_strings":["H. Lee Moffitt Cancer Ctr. & Rsrch. Institute, Tampa, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Ctr. & Rsrch. Institute, Tampa, FL, USA","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5102841436","display_name":"Daniel M. Sullivan","orcid":"https://orcid.org/0009-0003-0951-9781","observed_orcids":["https://orcid.org/0009-0003-0951-9781","https://orcid.org/0000-0002-2183-1773"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Sullivan","raw_affiliation_strings":["H. Lee Moffitt Cancer Ctr. & Rsrch. Institute, Tampa, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Ctr. & Rsrch. Institute, Tampa, FL, USA","institution_ids":["https://openalex.org/I3019308854"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.4281,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.69841585,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"112","issue":"11","first_page":"1945","last_page":"1945"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9775000214576721,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9775000214576721,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.012799999676644802,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tipifarnib","display_name":"tipifarnib","score":0.9959999918937683},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":1.0},{"id":"https://openalex.org/keywords/farnesyltransferase-inhibitors","display_name":"farnesyltransferase inhibitors","score":0.9520000219345093},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":1.0},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7149999737739563},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.8230000138282776},{"id":"https://openalex.org/keywords/acute-lymphoblastic-leukemia","display_name":"acute lymphoblastic leukemia","score":0.9800000190734863},{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia-blast-crisis","display_name":"chronic myeloid leukemia blast crisis","score":0.8740000128746033},{"id":"https://openalex.org/keywords/myelodysplastic-syndrome","display_name":"myelodysplastic syndrome","score":0.8140000104904175},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6110000014305115},{"id":"https://openalex.org/keywords/toxicity","display_name":"toxicity","score":0.47099998593330383},{"id":"https://openalex.org/keywords/akt-phosphorylation","display_name":"Akt phosphorylation","score":0.7039999961853027},{"id":"https://openalex.org/keywords/building-information-modeling","display_name":"building information modeling","score":0.6660000085830688},{"id":"https://openalex.org/keywords/bax","display_name":"Bax","score":0.9980000257492065},{"id":"https://openalex.org/keywords/nf-kb","display_name":"NF-kB","score":0.9829999804496765},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.652999997138977},{"id":"https://openalex.org/keywords/proteasome-activity","display_name":"proteasome activity","score":0.5559999942779541}],"concepts":[{"id":"https://openalex.org/C2777827897","wikidata":"https://www.wikidata.org/wiki/Q5436005","display_name":"Farnesyltransferase inhibitor","level":5,"score":0.7205320596694946},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.7133325338363647},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6449554562568665},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.5770071148872375},{"id":"https://openalex.org/C2778396349","wikidata":"https://www.wikidata.org/wiki/Q410994","display_name":"Farnesyltransferase","level":4,"score":0.5657027363777161},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5593501925468445},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.47759318351745605},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.47334814071655273},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.46987396478652954},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.42899036407470703},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.39604446291923523},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3441835641860962},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.17749792337417603},{"id":"https://openalex.org/C57790582","wikidata":"https://www.wikidata.org/wiki/Q901141","display_name":"Prenylation","level":3,"score":0.10801452398300171},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v112.11.1945.1945","doi":"https://doi.org/10.1182/blood.v112.11.1945.1945","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v112.11.1945.1945","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.7699999809265137}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2096654914","https://openalex.org/W34640787","https://openalex.org/W3016497539","https://openalex.org/W1996708547","https://openalex.org/W2402069987","https://openalex.org/W2994269292","https://openalex.org/W2089420365","https://openalex.org/W2002804283","https://openalex.org/W2045528227","https://openalex.org/W2119575895"],"abstract_inverted_index":{"Abstract":[0],"Combination":[1],"therapy":[2,120,156,531],"utilizing":[3],"2":[4,67,326,559],"novel":[5],"agents":[6,68],"with":[7,32,103,143,388,398,517,532],"independent":[8],"mechanisms":[9],"of":[10,21,47,94,97,118,154,186,216,221,328,365,391,401,420,448,470,476,485,542],"action":[11],"and":[12,56,74,78,128,137,166,173,196,209,213,237,241,274,295,310,318,343,362,397,427,511,539,550,569,572],"non-overlapping":[13],"toxicities":[14,331,353],"may":[15],"be":[16,576],"useful":[17],"in":[18,36,53,101,226,383,422,445,473,483,558],"the":[19,92,138,214,217,293,308,565],"setting":[20],"advanced":[22,104],"cancers.":[23],"Tipifarnib":[24],"(T)":[25],"is":[26,43,567],"an":[27],"orally":[28],"bioavailable":[29],"farnesyltranferase":[30],"inhibitor":[31,46],"documented":[33],"single-agent":[34],"activity":[35,64,243,435,458,555],"acute":[37,105],"myeloid":[38],"leukemia":[39,73],"(AML).":[40],"Bortezomib":[41],"(B)":[42],"a":[44,389,418,468,508],"broad":[45],"proteasomal":[48,242],"function,":[49],"approved":[50],"for":[51,69],"treatment":[52],"multiple":[54],"myeloma":[55,75],"mantle":[57],"cell":[58,76],"lymphoma.":[59],"Preclinical":[60],"studies":[61],"indicated":[62],"synergistic":[63],"between":[65,210],"these":[66],"eliciting":[70],"apoptosis":[71],"within":[72,247,374,413,436,459,547],"lines":[77],"ex-vivo":[79],"cells":[80,251,378],"adhered":[81],"to":[82,292,332,386,454,561,564],"fibronectin.":[83],"In":[84,552],"this":[85],"phase":[86],"I":[87],"combination":[88],"trial,":[89],"we":[90],"studied":[91],"effect":[93,96,117],"combined":[95,119,530],"T":[98,162,533],"plus":[99],"B":[100,167,535],"patients":[102,261,269,276,323,385,404,501,560],"leukemias.":[106],"Objectives:":[107],"The":[108,189],"primary":[109],"endpoint":[110],"was":[111,192,203,282,380,415,441,465,495,536,556],"toxicity":[112],"assessment.":[113],"Secondary":[114],"endpoints":[115],"included":[116],"on":[121,134,163,168,431],"signaling":[122,222],"intermediates,":[123],"including":[124],"p-AKT,":[125,486],"Bim,":[126,489],"Bax,":[127,235,487],"NF-kB,":[129],"as":[130,132,490],"well":[131,537],"effects":[133],"farnesyltransferase":[135],"(FT)":[136],"proteasome":[139],"activity.":[140],"Eligibility:":[141],"Patients":[142,160],"AML,":[144],"ALL,":[145],"or":[146,370,488],"CML-BC":[147],"who":[148],"had":[149,507,514,523],"received":[150,161,324],"<":[151],"3":[152,266],"cycles":[153,327],"prior":[155],"were":[157,176,224,244,270,367],"eligible.":[158],"Methods:":[159],"days":[164,169],"1\u201314":[165],"1,":[170],"4,":[171],"8,":[172,208,396],"11.":[174],"Cycles":[175],"repeated":[177],"every":[178],"21":[179],"days.":[180],"Dose":[181],"escalation":[182],"occurred":[183],"using":[184,231,253],"cohorts":[185],"3\u20136":[187],"patients.":[188],"starting":[190],"dose":[191,304],"T:":[193],"300":[194],"mg/m2":[195,199,317],"B:":[197,319],"1.0":[198],"Bone":[200],"marrow":[201,229],"aspirate":[202],"obtained":[204],"at":[205,265,307,408,438,462,472,497],"baseline,":[206,455],"day":[207,211,395,409,432,439,463,498],"15":[212],"start":[215],"next":[218],"cycle.":[219],"Measurement":[220],"intermediates":[223],"performed":[225],"Ficoll-enriched":[227],"leukemic":[228,460,548],"blasts":[230,461,549],"Western":[232,493],"Blot":[233],"(p-AKT,":[234],"Bim)":[236],"ELISA":[238],"(NF-kB).":[239],"FT":[240],"directly":[245],"measured":[246,381,491],"peripheral":[248,375],"blood":[249,376],"mononuclear":[250,377],"(PBMC)":[252,379],"previously":[254],"described":[255],"methods.":[256],"Results:":[257],"To":[258],"date,":[259,387],"27":[260],"have":[262,277,334],"been":[263,278],"enrolled":[264],"centers.":[267],"Four":[268,521],"ineligible":[271],"after":[272],"screening,":[273],"23":[275],"treated.":[279],"Median":[280],"age":[281],"69":[283],"years":[284],"(range":[285],"48\u201384)":[286],"Diagnosis:":[287],"AML=25,":[288],"ALL=1,":[289],"MDS=1.":[290],"Accrual":[291,563],"4th":[294,309],"final":[296,311],"dosing":[297,313],"cohort":[298,314],"has":[299],"occurred,":[300],"without":[301],"maximum":[302],"tolerated":[303,538],"being":[305],"reached":[306],"planned":[312],"(T:":[315],"600":[316],"1.3":[320],"mg/m2).":[321],"Six":[322],"\u2265":[325],"treatment.":[329],"Dose-limiting":[330],"date":[333],"included:":[335,354],"nausea/diarrhea":[336],"(1":[337,341,345],"patient),":[338,342],"sensory":[339,360],"neuropathy":[340],"fatigue":[344],"patient).":[346],"Common":[347],"drug-related":[348],"(>":[349],"10%)":[350],"non":[351],"dose-limiting":[352],"infection/febrile":[355],"neutropenia,":[356],"diarrhea,":[357],"nausea,":[358],"vomiting,":[359],"neuropathy,":[361],"fatigue,":[363],"most":[364],"which":[366],"grade":[368],"1":[369,428,505],"2.":[371],"FTase":[372],"inhibition":[373,393,407,541],"serially":[382],"8":[384,464],"median":[390,419,469],"70%":[392],"by":[394,417,467,492],"5":[399,446],"out":[400,447,475],"6":[402],"evaluable":[403],"having":[405],"sustained":[406],"22.":[410],"Proteasome":[411,434],"function":[412],"PBMCs":[414,437],"reduced":[416],"44.3%":[421],"7":[423,449],"patient":[424,450,506,513],"samples":[425,451],"pre-infusion":[426],"hour":[429],"post-infusion":[430],"8.":[433,499],"22":[440],"decreased":[442,466],"from":[443],"baseline":[444],"tested.":[452],"Compared":[453],"NF-kB":[456],"binding":[457],"39%":[471],"10":[474],"14":[477],"paired":[478],"samples.":[479],"No":[480],"significant":[481],"change":[482],"expression":[484],"Blot,":[494],"detected":[496],"Two":[500],"achieved":[502],"clinical":[503,554,571],"response;":[504],"complete":[509,515],"response":[510,516],"another":[512],"incomplete":[518],"count":[519],"recovery.":[520],"others":[522],"stable":[524],"disease":[525],"following":[526],"cycle":[527],"1.":[528],"Conclusion:":[529],"+":[534],"demonstrated":[540],"several":[543],"relevant":[544],"target":[545],"signals":[546],"PBMCs.":[551],"addition,":[553],"seen":[557],"date.":[562],"trial":[566],"ongoing":[568],"updated":[570],"pharmacodynamic":[573],"data":[574],"will":[575],"presented.":[577]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2016-07-22T00:00:00"}